miR-30a Regulates the Expression of CAGE and p53 and Regulates the Response to Anti-Cancer Drugs

  • Park, Deokbum (Department of Biochemistry, College of Natural Sciences, Kangwon National University) ;
  • Kim, Hyuna (Department of Biochemistry, College of Natural Sciences, Kangwon National University) ;
  • Kim, Youngmi (Department of Biochemistry, College of Natural Sciences, Kangwon National University) ;
  • Jeoung, Dooil (Department of Biochemistry, College of Natural Sciences, Kangwon National University)
  • Received : 2015.09.15
  • Accepted : 2016.01.12
  • Published : 2016.04.30


We have previously reported the role of miR-217 in anti-cancer drug-resistance. miRNA array and miRNA hybridization analysis predicted miR-30a-3p as a target of miR-217. miR-30a-3p and miR-217 formed a negative feedback loop and regulated the expression of each other. Ago1 immunoprecipitation and co-localization analysis revealed a possible interaction between miR-30a-3p and miR-217. miR-30a-3p conferred resistance to anti-cancer drugs and enhanced the invasion, migration, angiogenic, tumorigenic, and metastatic potential of cancer cells in CAGE-dependent manner. CAGE increased the expression of miR-30a-3p by binding to the promoter sequences of miR-30a-3p, suggesting a positive feedback loop between CAGE and miR-30a-3p. miR-30a-3p decreased the expression of p53, which showed the binding to the promoter sequences of miR-30a-3p and CAGE in anti-cancer drug-sensitive cancer cells. Luciferase activity assays showed that p53 serves as a target of miR-30a. Thus, the miR-30a-3p-CAGE-p53 feedback loop serves as a target for overcoming resistance to anti-cancer drugs.


anti-cancer drug-resistance;CAGE;feedback loop;miR-30a;p53


Supported by : National Research Foundation, Ministry for Health and Welfare


  1. Bojmar, L., Karlsson, E., Ellegard, S., Olsson, H., Bjornsson, B., Hallbook, O., Larsson, M., Stal, O., and Sandstrom, P. (2013). The role of microRNA-200 in progression of human colorectal and breast cancer. PLoS One 8, e84815.
  2. Chaudhary, P., Thamake, S.I., Shetty, P., and Vishwanatha, J.K. (2014). Inhibition of triple-negative and Herceptin-resistant breast cancer cell proliferation and migration by Annexin A2 antibodies. Br. J. Cancer 111, 2328-2341.
  3. Chen, Z., Ma, T., Huang, C., Zhang, L., Lv, X., Xu, T., Hu, T., and Li, J. (2013). miR-27a modulates the MDR1/P-glycoprotein expression by inhibiting FZD7/$\beta$-catenin pathway in hepatocellular carcinoma cells. Cell. Signal. 25, 2693-2701.
  4. Chen, W., Yang, Y., Chen, B., Lu, P., Zhan, L., Yu, Q., Cao, K., and Li, Q. (2014a). MiR-136 targets E2F1 to reverse cisplatin chemosensitivity in glioma cells. J. Neurooncol. 120, 43-53.
  5. Chen, W.X., Liu, X.M., Lv. M.M., Chen, L., Zhao, J.H., Zhong, S.L., Ji, M.H., Hu, Q., Luo, Z., Wu, J.Z., et al. (2014b). Exosomes from drug-resistant breast cancer cells transmit chemoresistance by a horizontal transfer of microRNAs. PLoS One 9, e95240.
  6. Cheng, W., Liu, T., Wan, X., Gao, Y., and Wang, H. (2012). MicroRNA- 199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells. FEBS J. 279, 2047-2059.
  7. Cho, B., Lim, Y., Lee, D.Y., Park, S.Y., Lee, H., Kim, W.H., Yang, H., Bang, Y.J., and Jeoung, D.I. (2002). Identification and characterization of a novel cancer/testis antigen gene CAGE. Biochem. Biophys. Res. Commun. 292, 715-726.
  8. Cho, B., Lee, H., Jeong, S., Bang, Y.J., Lee, H.J., Hwang, K.S., Kim, H.Y., Lee, Y.S., Kang, G.H., and Jeoung, D.I. (2003). Promoter hypomethylation of a novel cancer/testis antigen gene CAGE is correlated with its aberrant expression and is seen in premalignant stage of gastric carcinoma. Biochem. Biophys. Res. Commun. 307, 52-63.
  9. Fu, J., Xu, X., Kang, L., Zhou, L., Wang, S., Lu, J., Cheng, L., Fan, Z., Yuan, B., Tian, P., et al. (2014). miR-30a suppresses breast cancer cell proliferation and migration by targeting Eya2. Biochem. Biophys. Res. Commun. 445, 314-319.
  10. Guo, J., Feng, Z., Huang, Z., Wang, H., and Lu, W. (2014). Micro RNA-217 functions as a tumor suppressor gene and correlates with cell resistance to cisplatin in lung cancer. Mol. Cells 37, 664-671.
  11. Iwata, T., Fujita, T., Hirao, N., Matsuzaki, Y., Okada, T., Mochimaru, H., Susumu, N., Matsumoto, E., Sugano, K., Yamashita, N., et al. (2005). Frequent immune responses to a cancer/testis antigen, CAGE, in patients with microsatellite instability-positive endometrial cancer. Clin. Cancer Res. 11, 3949-3957.
  12. Jia, Z., Wang, K., Wang, G., Zhang, A., and Pu, P. (2013). MiR- 30a-5p antisense oligonucleotide suppresses glioma cell growth by targeting SEPT7. PLoS One 8, e55008.
  13. Kim, Y., Park, H., Park, D., Lee, Y.S., Choe, J., Hahn, J.H., Lee, H., Kim, Y.M., and Jeoung, D. (2010). Cancer/testis antigen CAGE exerts negative regulation on p53 expression through HDAC2 and confers resistance to anti-cancer drugs. J. Biol. Chem. 285, 25957-25968.
  14. Kim, Y., Park, D., Kim, H., Choi, M., Lee, H., Lee, Y.S., Choe, J., Kim, Y.M., and Jeoung, D. (2013). miR-200b and cancer/testis antigen CAGE form a feedback loop to regulate the invasion and tumorigenic and angiogenic responses of a cancer cell line to microtubule- targeting drugs. J. Biol. Chem. 288, 36502-36518.
  15. Kim, Y., Kim, H., Park, H., Park, D., Lee, H., Lee, Y.S., Choe, J., Kim, Y.M., and Jeoung, D. (2014). miR-326-histone deacetylase-3 feedback loop regulates the invasion and tumorigenic and angiogenic response to anti-cancer drugs. J. Biol. Chem. 289, 28019-28039.
  16. Lee, K.M., Nam, K., Oh, S., Lim, J., Kim, Y.P., Lee, J.W., Yu, J.H., Ahn, S.H., Kim, S.B., Noh, D.Y., et al. (2014). Extracellular matrix protein 1 regulates cell proliferation and trastuzumab resistance through activation of epidermal growth factor signaling. Breast Cancer Res. 16, 479.
  17. Liggins, A.P., Lim, S.H., Soilleux, E.J., Pulford, K., and Banham, A. H. (2010). A panel of cancer-testis genes exhibiting broadspectrum expression in haematological malignancies. Cancer Immun. 10, 8.
  18. Liu, Z., Chen, L., Zhang, X., Xu, X., Xing, H., Zhang, Y., Li, W., Yu, H., Zeng, J., and Jia, J. (2014). RUNX3 regulates vimentin expression via miR-30a during epithelial-mesenchymal transition in gastric cancer cells. J. Cell. Mol. Med. 18, 610-623.
  19. Mao, C., Zhang, J., Lin, S., Jing, L., Xiang, J., Wang, M., Wang, B., Xu, P., Liu, W., Song, X., et al. (2014). MiRNA-30a inhibits AECs- II apoptosis by blocking mitochondrial fission dependent on Drp-1. J. Cell. Mol. Med. 18, 2404-2416.
  20. Mathew, L.K., Lee, S.S., Skuli, N., Rao, S., Keith, B., Nathanson, K.L., Lal, P., Simon, M.C. (2014). Restricted expression of miR- 30c-2-3p and miR-30a-3p in clear cell renal cell carcinomas enhances $HIF2{\alpha}$ activity. Cancer Discov. 4, 53-60.
  21. Nishioka, C., Ikezoe, T., Yang, J., Nobumoto, A., Tsuda, M., and Yokoyama, A. (2014). Downregulation of miR-217 correlates with resistance of Ph (+). leukemia cells to ABL tyrosine kinase inhibitors. Cancer Sci. 105, 297-307.
  22. Perez-Rivas, L.G., Jerez, J.M., Carmona, R., de Luque, V., Vicioso, L., Claros, M.G., Viguera, E., Pajares, B., Sanchez, A., Ribelles, N., et al. (2014). A microRNA signature associated with early recurrence in breast cancer. PLoS One 9, e91884.
  23. Por, E., Byun, H.J., Lee, E.J., Lim, J.H., Jung, S.Y., Park, I., Kim, Y.M., Jeoung, D.I., and Lee, H. (2010). The cancer/testis antigen CAGE with oncogenic potential stimulates cell proliferation by upregulating cyclins D1 and E in an AP-1- and E2F-dependent manner. J. Biol. Chem. 285, 14475-14485.
  24. Rexer, B.N., Ghosh, R., Narasanna, A., Estrada, M.V., Chakrabarty, A., Song, Y., Engelman, J.A., and Arteaga, C.L. (2013). Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2. Clin. Cancer Res 19, 5390-5401.
  25. Song, S.J., Ito, K., Ala, U., Kats, L., Webster, K., Sun, S.M., Jongen-Lavrencic, M., Manova-Todorova, K., Teruya-Feldstein, J., Avigan, D.E., et al. (2013). The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation. Cell Stem Cell 13, 87-101.
  26. Wang, W., Lin, H., Zhou, L., Zhu, Q., Gao, S., Xie, H., Liu, Z., Xu, Z., Wei, J., Huang, X., et al. (2013). MicroRNA-30a-3p inhibits tumor proliferation, invasiveness and metastasis and is downregulated in hepatocellular carcinoma. Eur. J. Surg. Oncol. 40, 1586-1594.
  27. Wang, H.Y., Li, Y.Y., Fu, S., Wang, X.P., Huang, M.Y., Zhang, X., Shao, Q., Deng, L., Zeng, M.S., Zeng, Y.X., et al. (2014). MicroRNA- 30a promotes invasiveness and metastasis in vitro and in vivo through epithelial-mesenchymal transition and results in poor survival of nasopharyngeal carcinoma patients. Exp. Biol. Med. (Maywood). 239, 891-898.
  28. Wu, Z.B., Li, W.Q., Lin, S.J., Wang, C.D., Cai, L., Lu, J.L., Chen, Y.X., Su, Z.P., Shang, H.B., Yang, W.L., et al. (2014). MicroRNA expression profile of bromocriptine-resistant prolactinomas. Mol. Cell. Endocrinol. 395, 10-18.

Cited by

  1. A cancer/testis antigen, NY-SAR-35, induces EpCAM, CD44, and CD133, and activates ERK in HEK293 cells vol.484, pp.2, 2017,
  2. Identification of epigenetic interactions between miRNA and DNA methylation associated with gene expression as potential prognostic markers in bladder cancer vol.10, pp.S1, 2017,
  3. Titanium dioxide aggregating nanoparticles induce autophagy and under-expression of microRNA 21 and 30a in A549 cell line: A comparative study with cobalt(II, III) oxide nanoparticles vol.42, 2017,
  4. MiR-30a: A Novel Biomarker and Potential Therapeutic Target for Cancer vol.2018, pp.1687-8469, 2018,
  5. A p53/miR-30a/ZEB2 axis controls triple negative breast cancer aggressiveness pp.1476-5403, 2018,